DIM

Sartorius Stedim BiotechENXTPA:DIM Stock Report

Market Cap

€48.2b

7D

-4.6%

1Y

74.5%

Updated

18 Sep, 2021

Data

Company Financials +
DIM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance5/6
Financial Health5/6
Dividends0/6

DIM Overview

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide.

Rewards

Earnings are forecast to grow 13.4% per year

Earnings have grown 22.9% per year over the past 5 years

Risk Analysis

No risks detected for DIM from our risk checks.

Sartorius Stedim Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sartorius Stedim Biotech
Historical stock prices
Current Share Price€523.00
52 Week High€271.20
52 Week Low€551.00
Beta0.086
1 Month Change5.36%
3 Month Change37.34%
1 Year Change74.45%
3 Year Change360.39%
5 Year Change692.54%
Change since IPO6,263.82%

Recent News & Updates

Aug 21
Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt

Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

DIMFR Life SciencesFR Market
7D-4.6%-1.8%-1.8%
1Y74.5%58.4%32.8%

Return vs Industry: DIM exceeded the French Life Sciences industry which returned 58.4% over the past year.

Return vs Market: DIM exceeded the French Market which returned 32.8% over the past year.

Price Volatility

Is DIM's price volatile compared to industry and market?
DIM volatility
DIM Beta0.086
Industry Beta0.56
Market Beta1

Stable Share Price: DIM is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DIM's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18708,746Joachim Kreuzburghttps://www.sartorius.com

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses.

Valuation

Is Sartorius Stedim Biotech undervalued compared to its fair value and its price relative to the market?

101.46x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DIM (€523) is trading above our estimate of fair value (€145.96)

Significantly Below Fair Value: DIM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DIM is poor value based on its PE Ratio (101.5x) compared to the European Life Sciences industry average (54.2x).

PE vs Market: DIM is poor value based on its PE Ratio (101.5x) compared to the French market (21.2x).


Price to Earnings Growth Ratio

PEG Ratio: DIM is poor value based on its PEG Ratio (7.6x)


Price to Book Ratio

PB vs Industry: DIM is overvalued based on its PB Ratio (28.9x) compared to the XE Life Sciences industry average (5.2x).


Future Growth

How is Sartorius Stedim Biotech forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

13.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIM's forecast earnings growth (13.4% per year) is above the savings rate (0.4%).

Earnings vs Market: DIM's earnings (13.4% per year) are forecast to grow faster than the French market (12.2% per year).

High Growth Earnings: DIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIM's revenue (14.4% per year) is forecast to grow faster than the French market (6.2% per year).

High Growth Revenue: DIM's revenue (14.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIM's Return on Equity is forecast to be high in 3 years time (27.1%)


Past Performance

How has Sartorius Stedim Biotech performed over the past 5 years?

22.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIM has high quality earnings.

Growing Profit Margin: DIM's current net profit margins (19.9%) are higher than last year (15.9%).


Past Earnings Growth Analysis

Earnings Trend: DIM's earnings have grown significantly by 22.9% per year over the past 5 years.

Accelerating Growth: DIM's earnings growth over the past year (86.6%) exceeds its 5-year average (22.9% per year).

Earnings vs Industry: DIM earnings growth over the past year (86.6%) underperformed the Life Sciences industry 86.6%.


Return on Equity

High ROE: DIM's Return on Equity (28.4%) is considered high.


Financial Health

How is Sartorius Stedim Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: DIM's short term assets (€1.3B) exceed its short term liabilities (€792.4M).

Long Term Liabilities: DIM's short term assets (€1.3B) exceed its long term liabilities (€1.0B).


Debt to Equity History and Analysis

Debt Level: DIM's debt to equity ratio (32%) is considered satisfactory.

Reducing Debt: DIM's debt to equity ratio has increased from 18.9% to 32% over the past 5 years.

Debt Coverage: DIM's debt is well covered by operating cash flow (108.8%).

Interest Coverage: DIM's interest payments on its debt are well covered by EBIT (712.2x coverage).


Balance Sheet


Dividend

What is Sartorius Stedim Biotech current dividend yield, its reliability and sustainability?

0.13%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DIM's dividend (0.13%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.27%).

High Dividend: DIM's dividend (0.13%) is low compared to the top 25% of dividend payers in the French market (3.88%).


Stability and Growth of Payments

Stable Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DIM is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DIM's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average board tenure


CEO

Joachim Kreuzburg (56 yo)

no data

Tenure

€3,552,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH.Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...


CEO Compensation Analysis

Compensation vs Market: Joachim's total compensation ($USD4.17M) is about average for companies of similar size in the French market ($USD3.29M).

Compensation vs Earnings: Joachim's compensation has increased by more than 20% in the past year.


Board Members

Experienced Board: DIM's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sartorius Stedim Biotech S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Stedim Biotech S.A.
  • Ticker: DIM
  • Exchange: ENXTPA
  • Founded: 1870
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €48.210b
  • Shares outstanding: 92.18m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Stedim Biotech S.A.
  • Zone Industrielle Les Paluds
  • Avenue de Jouques – CS 91051
  • Aubagne
  • Provence-Alpes-Côte d'Azur
  • 13781
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 17:32
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.